Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

BCBA/ROSE stock hub

BCBA/ROSE has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BCBA/ROSEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

Buenos Aires Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

BCBA/ROSE

In the news

Latest news · BCBA/ROSE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 14.1P50 17.9P75 19.4

Trailing P/En/a

P25 25P50 30P75 39

ROE-260.6

P25 6.8P50 15.6P75 45.1

ROIC-291.8

P25 9P50 19.1P75 21.2

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BCBA/ROSE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

180

Groups with data

Currency

ARS

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Argentina
Country code	AR
Enterprise value	ARS 8B
Exchange	Buenos Aires Stock Exchange
Financial currency	ARS
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	ARROSE010025
Last refreshed	2026-05-10
Market cap	ARS 7B
Price	ARS 164
Price currency	ARS
Sector	Healthcare
Sic	2834
Symbol	bcba/ROSE
Website	https://www.rosenbusch.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-65.83%
EV Earnings	-1.74x
EV/FCF	20.1x
EV/Sales	1.25x
FCF yield	5.69%
P/B ratio	-13.27x
P/S ratio	1.09x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-52.61%
EBITDA Margin	-49.61%
FCF margin	6.21%
Gross margin	-4.47%
Gross Profit	ARS -286M
Gross Profit Growth Q	-50.06%
Net Income	ARS -4.6B
Pretax Margin	-69.7%
Profit Margin	-71.8%
ROA	-23.84
Roa5y	2.53
ROCE	-295.5
ROE	-260.6
Roe5y	-57.57
ROIC	-291.8
Roic5y	-31.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	43.93%
Cagr15y	36.31%
Cagr1y	92.35%
Cagr20y	25.9%
Cagr3y	122.16%
Cagr5y	78.32%
FCF Growth	-43.71%
FCF Growth3 Y	77.82%
FCF Growth5 Y	44.66%
OCF Growth	-43.1%
OCF Growth3 Y	38.77%
OCF Growth5 Y	44.18%
Revenue Growth	-41.17x
Revenue Growth Q	-10.49x
Revenue Growth3 Y	14.41x
Revenue Growth5 Y	50x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	ARS 0.72
Assets	ARS 7.7B
Cash	ARS 712.3M
Current Assets	ARS 5.7B
Current Liabilities	ARS 6.6B
Debt	ARS 1.5B
Debt FCF	ARS 3.65
Equity	ARS -526.2M
Interest Coverage	-2.04
Liabilities	ARS 8.3B
Long Term Assets	ARS 2B
Long Term Liabilities	ARS 1.7B
Net Cash	ARS -737.7M
Net Cash By Market Cap	ARS -10.56
Net Debt FCF	ARS 1.85
Tangible Book Value	ARS -800.2M
Tangible Book Value Per Share	ARS -18.79
WACC	19.08

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	0.87
Inventory Turnover	1.99
Net Working Capital	ARS -1.1B
Quick ratio	0.4
Working Capital	ARS -872.4M
Working Capital Turnover	ARS 5.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend per share	ARS 0
Last Dividend	ARS 0.02

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	3,713.95%
1Y total return	92.26%
200-day SMA	195.5
3Y total return	996.99%
50-day SMA	177.1
50-day SMA vs 200-day SMA	50under200
5Y total return	1,702.2%
All Time High	450
All Time High Change	-63.56%
All Time High Date	2025-06-09
All Time Low	0.27
All Time Low Change	60,889.22%
All Time Low Date	1999-09-16
ATR	10.17
Beta	0.02
Beta1y	0.26
Beta2y	0.35
Ch YTD	-31.81
High	165.5
High52	450
High52 Date	2025-06-09
High52ch	-63.56%
Low	158.5
Low52	85
Low52 Date	2025-05-08
Low52ch	92.94%
Ma50ch	-7.42%
Price vs 200-day SMA	-16.11%
RSI	46.13
RSI Monthly	52.72
RSI Weekly	43.21
Sharpe ratio	1.02x
Sortino ratio	1.97
Tr YTD	-31.81
Tr15y	10,321.58%
Tr1m	-16.96%
Tr1w	-3.24%
Tr3m	-26.62%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	ARS -3.4B
Operating margin	-52.61

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	8,497,986%
Net Borrowing	-839,331,035
Shares Insiders	80.05%
Shares Out	42,589,465
Shares Qo Q	0%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	ARS 397.8M
Average Volume	70,188.7x
Bv Per Share	-18.79
CAPEX	ARS -12.1M
Ch10y	3,714
Ch15y	10,319.3
Ch1m	-16.96
Ch1w	-3.24
Ch1y	92.26
Ch20y	9,479.4
Ch3m	-26.62
Ch3y	997
Ch5y	1,702.2
Change	-0.61%
Change From Open	1.86
Close	165
Days Gap	-2.42
Depreciation Amortization	192,076,301
Dollar Volume	25,432,300
Earnings Date	2026-04-01
EBIT	ARS -3.4B
EBITDA	ARS -3.2B
EPS	ARS -108
F Score	3
FCF	ARS 397.8M
FCF EV Yield	4.97x
FCF Per Share	ARS 9.34
Financing CF	-839,331,035
Fiscal Year End	December
Founded	1,917
Income Tax	ARS 50.9M
Investing CF	-12,134,976
Is Primary Listing	1
Last Earnings Date	2026-02-13
Last Report Date	2025-12-31
Last Split Date	2011-11-16
Last Split Type	Forward
Ma150	194.3
Ma150ch	-15.58%
Ma20	165.3
Ma20ch	-0.8%
Net CF	-441,579,271
Open	161
P FCF Ratio	17.56
P OCF Ratio	17.04
Position In Range	78.57
Ppne	1,992,118,491
Price Date	2026-05-08
Relative Volume	2.21x
Revenue	6,403,594,170x
Tax By Revenue	0.79x
Tr20y	9,917.12%
Volume	155,075
Z Score	-1.83

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BCBA/ROSE pay a dividend?

Capital-return profile for this ticker.

Performance

BCBA/ROSE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BCBA/ROSE?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

+80.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

n/a

Negative means the company is buying back shares.

Technical

BCBA/ROSE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.1

Neutral momentum band

Price vs 200-day MA

-16.1%

50/200-day relationship not available

Beta (5Y)

0.02

Less volatile than the market

Sharpe ratio

1.02

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BCBA/ROSE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bcba/ROSE stock rating?

bcba/ROSE is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bcba/ROSE analysis?

The full report lives at /stocks/bcba/ROSE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bcba/ROSE?

The latest report frames bcba/ROSE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bcba/ROSE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.